Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Cash & Equivalents	62,689	115,378	219,433	125,022	268,651
Short-Term Investments	3,265	63,325	3,058	176,390	25,584
Trading Asset Securities	-	-	-	-	9,035
Cash & Short-Term Investments	65,954	178,702	222,492	301,412	303,270
Cash Growth	-63.09%	-19.68%	-26.18%	-0.61%	-33.98%
Accounts Receivable	3,819	607.07	391.6	132.72	-
Receivables	3,819	607.07	391.6	132.72	-
Inventory	32,757	26,995	18,103	7,146	2,157
Prepaid Expenses	2,086	1,641	2,733	2,731	-
Other Current Assets	3,846	2,059	6,632	53.44	6,139
Total Current Assets	108,462	210,004	250,352	311,476	311,566
Property, Plant & Equipment	427,987	341,657	327,062	310,438	38,342
Long-Term Investments	-	-	-	-	74,710
Goodwill	11,967	10,530	10,785	10,192	-
Other Intangible Assets	33,047	30,056	31,327	29,877	4,288
Long-Term Deferred Charges	154,793	152,882	91,643	78,843	61,024
Other Long-Term Assets	1,422	525.18	551.5	775.14	9,883
Total Assets	737,678	745,654	711,720	741,600	499,813

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Accounts Payable	5,287	5,864	2,282	462.15	2,624
Accrued Expenses	3,843	4,872	5,975	6,150	4,923
Short-Term Debt	80,672	117,454	36,954	31,188	-
Current Portion of Long-Term Debt	-	-	10,891	31,176	-
Current Portion of Leases	1,505	1,018	950.81	1,682	1,593
Other Current Liabilities	53,347	36,113	88,805	64,231	32,654
Total Current Liabilities	144,654	165,322	145,857	134,888	41,794
Long-Term Debt	21,777	32,498	40,247	50,190	-
Long-Term Leases	2,781	641.93	624.04	1,326	2,656
Long-Term Unearned Revenue	-	-	-	-	25,427
Long-Term Deferred Tax Liabilities	33,760	7,310	7,755	7,368	-
Other Long-Term Liabilities	30,312	31,572	1,734	1,593	0
Total Liabilities	233,282	237,343	196,219	195,365	69,877

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Common Stock	810,409	713,096	730,340	690,175	679,713
Additional Paid-In Capital	-35,919	-31,606	7,865	7,286	7,175
Retained Earnings	-399,904	-266,271	-294,797	-246,151	-259,601
Comprehensive Income & Other	57,444	-4,209	-4,321	-798.76	2,649
Total Common Equity	432,029	411,010	439,087	450,511	429,936
Minority Interest	72,367	97,301	76,414	95,724	-
Shareholders' Equity	504,396	508,311	515,502	546,235	429,936
Total Liabilities & Equity	737,678	745,654	711,720	741,600	499,813

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Total Debt	106,734	151,612	89,667	115,561	4,249
Net Cash (Debt)	-40,780	27,090	132,825	185,851	299,020
Net Cash Growth	-	-79.60%	-28.53%	-37.85%	-33.78%
Net Cash Per Share	-678.57	450.78	2215.00	3092.56	4975.70
Filing Date Shares Outstanding	60.1	59.66	300.48	300.48	300.48
Total Common Shares Outstanding	60.1	59.66	300.48	300.48	300.48
Working Capital	-36,192	44,682	104,494	176,588	269,771
Book Value Per Share	7188.63	6889.58	1461.28	1499.30	1430.83
Tangible Book Value	387,015	370,424	396,976	410,442	425,647
Tangible Book Value Per Share	6439.63	6209.25	1321.13	1365.95	1416.55
Land	135,497	27,332	27,704	26,567	12,055
Buildings	139,016	136,640	77,472	76,415	-
Machinery	97,842	79,512	72,427	51,848	10,175
Construction In Progress	24,950	110,263	152,876	169,147	15,415

Data Source: S&P Global Market Intelligence Last updated: Sep 21, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 30, 2026

Data Sources Report a data error